← Back to Clinical Trials
Recruiting NCT06281795

NCT06281795 Neuromodulation of the Autonomic Nervous System in Athletes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06281795
Status Recruiting
Phase
Sponsor Bakulev Scientific Center of Cardiovascular Surgery
Condition Efficacy, Self
Study Type INTERVENTIONAL
Enrollment 125 participants
Start Date 2024-04-01
Primary Completion 2026-01-31

Trial Parameters

Condition Efficacy, Self
Sponsor Bakulev Scientific Center of Cardiovascular Surgery
Study Type INTERVENTIONAL
Phase N/A
Enrollment 125
Sex ALL
Min Age 15 Years
Max Age 35 Years
Start Date 2024-04-01
Completion 2026-01-31
Interventions
tVNS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.

Eligibility Criteria

Inclusion Criteria: * Professional athletes over the age of 15 and under the age of 35; * Cyclic sports (swimming, modern pentathlon, athletics, triathlon); * Difficult coordination sports (dance sports, rhythmic gymnastics); * Sports category: no lower than candidate for master of sports; * Voluntary informed consent. Exclusion Criteria: * Atypical and unrelated to physical exertion changes on the ECG (T wave inversion, st-segment depression, pathological Q waves, signs of left atrial enlargement, signs of right ventricular hypertrophy, ventricular pre-excitation, complete right or left bundle branch block, prolonged or shortened Q-T interval, Brugada-like early repolarization); * Heart rhythm and conduction disorders (frequent ventricular and supraventricular extrasystoles, first-degree atrioventricular block (P-Q \> 0.21 s, not shortened during hyperventilation or physical exertion), second or third degree); * Expressed sinus bradycardia with resting heart rate \< 40 bpm; * Taking g

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology